FIVE at FIVE AU: Iron ore cops a belting and energy prices could stay high until 2025
All the major banks have now lifted interest rates in line with the Reserve Bank...
All the major banks have now lifted interest rates in line with the Reserve Bank...
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune...
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new...
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a...
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.